Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
J Fr Ophtalmol ; 38(10): 974-82, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26545331

RESUMEN

INTRODUCTION: Cat-scratch disease (CSD) is a systemic infectious disease. The most well-known posterior segment presentation is neuroretinitis with a macular star. In this study, we present a case series emphasising the heterogeneity of the disease and the various posterior segment manifestations. MATERIALS AND METHODS: A retrospective case series of consecutive patients presenting with posterior segment CSD, over a 5-year period (2010 to 2015), at two ophthalmological centres in Midi-Pyrénées. RESULTS: Twelve patients (17 eyes) were included, of whom 11 (92%) presented with rapidly decreasing visual acuity, with 6 of these (50%) extremely abrupt. CSD was bilateral in 5 (42% of all patients). Posterior manifestations were: 12 instances of optic nerve edema (100%), 8 of focal chorioretinitis (67%) and only 6 of the classic macular edema with macular star (25% at first examination, but 50% later). Other ophthalmological complications developed in three patients; one developed acute anterior ischemic optic neuropathy, one a retrohyaloid hemorrhage and one a branch retinal artery occlusion, all secondary to occlusive focal vasculitis adjacent to focal chorioretinitis. CONCLUSION: Classical neuroretinitis with macular star is not the only clinical presentation of CSD. Practitioners should screen for Bartonella henselae in all patients with papillitis or focal chorioretinitis.


Asunto(s)
Enfermedad por Rasguño de Gato/complicaciones , Edema Macular/etiología , Papiledema/etiología , Segmento Posterior del Ojo/patología , Retinitis/etiología , Corticoesteroides/uso terapéutico , Adulto , Animales , Antibacterianos/uso terapéutico , Enfermedad por Rasguño de Gato/tratamiento farmacológico , Enfermedad por Rasguño de Gato/epidemiología , Enfermedad por Rasguño de Gato/patología , Gatos , Niño , Quimioterapia Combinada , Femenino , Humanos , Mácula Lútea/patología , Edema Macular/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Estaciones del Año , Agudeza Visual , Adulto Joven
3.
Acta Ophthalmol Scand ; 78(2): 196-9, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10794256

RESUMEN

BACKGROUND AND OBJECTIVES: We carried out a prospective study in order to evaluate the efficacy and safety of peribulbar anaesthesia supplemented by a sub-Tenon injection in case of inadequate analgesia during vitreoretinal surgery. METHODS: We performed 300 consecutive vitreoretinal procedures. Patients received a mean volume of 17+/-4.5 ml of a mixture of etidocaine 1%, bupivacaine 0.50% and hyaluronidase (25 UI/ml). Supplementation was represented by a sub-Tenon infiltration of lidocaine 2% (2 or 3 ml). This volume was not included in the mean volume. RESULTS: Analgesia was adequate throughout surgery without any supplementation in 85% of cases and with a sub-Tenon infiltration in 99%. Akinesia was complete in 82%, mild in 15% and absent in 3% of cases. The sub-Tenon injection was performed immediately before starting the procedure in 58% of cases and during the surgery with a delay of 80+/-21 min in 42%. Eleven patients (3.66%) were agitated during surgery and two of them needed a general anaesthesia to allow for the procedure. Generalised epilepsy was encountered in two patients (0.66%) immediately after the peribulbar injection in one patient and 15 min later in the other. The systolic blood pressure severely decreased between 60 to 70 mm Hg 40 min after the accomplishment of the peribulbar in 2 patients and at 90 min in 2 others. CONCLUSION: Our results demonstrate that peribulbar anaesthesia alone offers excellent analgesia in 85% of patients and supplemented by a sub-Tenon injection in 99%.


Asunto(s)
Anestesia Local/métodos , Anestésicos Combinados/administración & dosificación , Anestésicos Locales/administración & dosificación , Tejido Conectivo/efectos de los fármacos , Enfermedades de la Retina/cirugía , Vitrectomía , Adulto , Anciano , Anciano de 80 o más Años , Analgesia , Bloqueo Nervioso Autónomo/métodos , Bupivacaína/administración & dosificación , Etidocaína/administración & dosificación , Femenino , Humanos , Hialuronoglucosaminidasa/administración & dosificación , Inyecciones , Masculino , Persona de Mediana Edad , Bloqueo Nervioso , Órbita , Estudios Prospectivos , Seguridad
6.
Eur J Ophthalmol ; 6(3): 287-92, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8908436

RESUMEN

The efficacy and safety of ciprofloxacin ophthalmic solution 0.3% and norfloxacin ophthalmic solution 0.3% in the treatment of bacterial conjunctivitis and blepharitis were compared in a double masked randomised study. A total of 131 patients, 65 treated with ciprofloxacin (42 with conjunctivitis and 23 with blepharitis) and 66 treated with norfloxacin (39 with conjunctivitis and 27 with blepharitis) were enrolled in the study at five centres in France. In the efficacy population, pathogens were eradicated or reduced in 96% (24/25) of patients in the ciprofloxacin group and 89% (24/27) in the norfloxacin group. There was no difference between treatments with regard to eradication of particular pathogens. In the efficacy population, clinical cure or improvement was seen in 96% of the patients (24/25 in the ciprofloxacin group and 26/27 in the norfloxacin group). There were no significant differences between ciprofloxacin and norfloxacin with respect to improvements in four symptoms or ten clinical signs. No serious treatment-related adverse events were reported and both ciprofloxacin and norfloxacin were well tolerated.


Asunto(s)
Antiinfecciosos/uso terapéutico , Blefaritis/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Conjuntivitis Bacteriana/tratamiento farmacológico , Norfloxacino/uso terapéutico , Antiinfecciosos/administración & dosificación , Antiinfecciosos/efectos adversos , Bacterias/aislamiento & purificación , Blefaritis/microbiología , Blefaritis/patología , Ciprofloxacina/administración & dosificación , Conjuntiva/microbiología , Conjuntivitis Bacteriana/etiología , Conjuntivitis Bacteriana/patología , Método Doble Ciego , Evaluación de Medicamentos , Párpados/microbiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Norfloxacino/administración & dosificación , Norfloxacino/efectos adversos , Soluciones Oftálmicas , Estudios Prospectivos , Seguridad , Resultado del Tratamiento
7.
Curr Eye Res ; 15(7): 701-7, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8670776

RESUMEN

PURPOSE: A clinico-histopathological cross correlation was made to study the mechanism of tissue damage in toxoplasmic retino-choroiditis during an experimental reactivation of chronic toxoplasmosis and to compare the influence of treatment by sulfadiazine on the retinal lesions. METHODS: Chronically infected Swiss-Webster mice were treated, six weeks after infection, with an avirulent strain of Toxoplasma gondii (Beverley strain) with polyclonal rabbit antibody directed against murine interferon gamma. RESULTS: Mice treated by anti-interferon gamma developed clinical lesions between day 5 and day 30 (lesions including single foci of retinochoroiditis, multifocal lesions or diffuse areas of retinal necrosis). These lesions did not arise from borders of pre-existing scars. The retina was photographed with an operating microscope fitted with a 90 diopter lens. Biological study showed a significant rise of parasitic loads in the eye and brain. Histological examination is in favour of free organism dissemination via retinal vessels; the lesions are restricted to the inner retina and ciliary body, the parasites migrated from extra-ocular cysts via the vasculature. No cysts were seen at the beginning of the study; they were found at the scar phase and appeared in mice treated with sulfadiazine. The clinical lesions were not caused by cysts but by coagulated necrosis in the retinal tissue. Parasite migration may have played a trigger role. CONCLUSIONS: The retinal damage was constituted either as a result of a toxic effect of the organisms or as a hypertensive reaction to the toxoplasma organism. The results of this study showed that the treatment with anti interferon gamma was sufficient to reactivate chronic infection.


Asunto(s)
Anticuerpos/farmacología , Interferón gamma/antagonistas & inhibidores , Toxoplasmosis Ocular/etiología , Corticoesteroides/farmacología , Animales , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Conejos , Recurrencia , Factores de Tiempo , Toxoplasma/aislamiento & purificación , Toxoplasmosis Ocular/parasitología , Toxoplasmosis Ocular/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA